Medline (NASDAQ:MDLN) Major Shareholder Private Ltd Gic Sells 1,976,618 Shares of Stock

Medline (NASDAQ:MDLN) major shareholder Private Ltd Gic sold 1,976,618 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $35.60, for a total value of $70,367,600.80. Following the transaction, the insider owned 25,264,760 shares of the company’s stock, valued at $899,425,456. This trade represents a 7.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Private Ltd Gic also recently made the following trade(s):

• On Thursday, August 6th, Private Ltd Gic sold 271,994 shares of Medline stock. The stock was sold at an average price of $35.33, for a total value of $9,609,548.02.

Medline Price Performance

Shares of MDLN stock opened at $35.23 on Friday. The stock has a 50 day moving average price of $38.22 and a 200 day moving average price of $41.72. Medline has a 52-week low of $32.81 and a 52-week high of $50.88. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.51 and a current ratio of 4.33. The firm has a market capitalization of $46.28 billion and a P/E ratio of 110.09.

Medline (NASDAQ:MDLN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.32 by $0.18. The business had revenue of $7.68 billion during the quarter. As a group, sell-side analysts predict that Medline will post 1.49 earnings per share for the current year.

Institutional Investors Weigh In On Medline

A number of institutional investors have recently added to or reduced their stakes in the stock. Carlyle Group Inc. purchased a new stake in shares of Medline during the fourth quarter valued at about $9,042,728,000. H&F Corporate Investors X Ltd. purchased a new position in shares of Medline in the 4th quarter worth approximately $4,179,591,000. Vanguard Group Inc. purchased a new position in shares of Medline in the 4th quarter worth approximately $793,278,000. Morgan Stanley bought a new position in shares of Medline during the 4th quarter worth approximately $636,807,000. Finally, Capital Research Global Investors purchased a new stake in Medline during the fourth quarter valued at approximately $620,937,000.

Key Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter earnings of $0.50 per share, well above the $0.32 analyst consensus, on $7.69 billion in revenue. The company also raised its 2026 organic-sales-growth outlook to 9%–10%, signaling continued demand for its medical-supply products. Medline Q2 Earnings Snapshot Medline raises 2026 organic sales outlook
• Positive Sentiment: Analysts remain constructive: BTIG reiterated a Buy rating with a $55 price target, while Truist and Stifel maintained Buy ratings with targets of $47 and $45, respectively. Although both firms reduced their targets, they still imply substantial upside from recent levels. BTIG Medline rating
• Neutral Sentiment: The positive sales outlook was accompanied by a reduction in projected 2026 adjusted EBITDA to $3.3 billion–$3.4 billion. This suggests strong revenue momentum but near-term margin or cost pressures that could limit earnings growth.
• Negative Sentiment: Major shareholder GIC Private Ltd. sold approximately 2.25 million Medline shares across August 5–6 for roughly $80 million, reducing its holdings by about 8.3% overall. Large-holder selling can add supply and weigh on investor sentiment. SEC ownership filing
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations following previously reported FDA violations. The announcements do not establish wrongdoing, but they introduce potential legal, regulatory, and reputational risks for Medline. Kaplan Fox Medline investigation Kessler Topaz Medline investigation

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on MDLN. Weiss Ratings upgraded shares of Medline from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday. Stifel Nicolaus lowered their price objective on shares of Medline from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday. BTIG Research restated a “buy” rating and issued a $55.00 target price on shares of Medline in a research note on Friday, July 31st. Truist Financial dropped their price target on Medline from $56.00 to $47.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Tigress Financial upped their price target on shares of Medline from $60.00 to $62.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $48.50.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.